Benefits of using empagliflozin in patients with type 2 diabetes mellitus and liver cirrhosis
AbstractDue to the rapid increase of the prevalence of type 2 diabetes mellitus (T2DM) worldwide, the practically significant interest of the scientific community in the search for new glucose-lowering drugs is growing in parallel. The article demonstrates the results of a study that compares two classes of new oral hypoglycemic drugs - sodium glucose co-transporter type 2 inhibitors (iNGLT-2) (empagliflozin), and a selective reversible competitive inhibitor of dipetidyl peptidase-4 (saxagliptin) in patients with T2DM and liver cirrhosis. The study revealed the advantages of using iNGLT-2 agents in patients of this group.
Keywords:type 2 diabetes mellitus, liver cirrhosis, type 2 sodium-glucose cotransporter inhibitors, empagliflozin
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Morgunov L. Yu., Mamedguseynov H.S. Benefits of using empagliflozin in patients with type 2 diabetes mellitus and liver cirrhosis. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (4): 103-5. DOI: https://doi.org/10.33029/2304-9529-2021-10-4-103-105 (in Russian)